MedTrace Logo

Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer

NCT04703244 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 999

Last updated 2026-03-03

No results posted yet for this study

Summary

Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (\>50%) risk of future life-threatening recurrences and death.

Conditions

Interventions

PROCEDURE

chemotherapy or endocrine therapy for breast cancer

Collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed.

Sponsors & Collaborators

Principal Investigators

  • Judy C. Boughey, M.D. · Mayo Clinic

  • Matthew P. Goetz, M.D. · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-13
Primary Completion
2041-01-15
Completion
2042-01-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04703244 on ClinicalTrials.gov